Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical…
2,020$
0,50%
Echtzeit-Aktienkurs Organovo Holdings Inc.
Bid:
Ask:
Nachrichten zur Organovo Holdings Inc. Aktie
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused…
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
ONVO announced the pricing of a public offering consisting of 6,562,500 shares of common stock (or pre-funded warrants in lieu…